{"filing":{"accession_number":"0001654954-26-006554","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-07-09","report_date":null,"primary_document":"a6054l.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426006554/a6054l.htm"},"events":[{"id":16780,"run_id":15008,"accession_number":"0001654954-26-006554","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"AstraZeneca announced that its Phase III CARDIO-TTRansform trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy \"did not meet the primary efficacy endpoint\" of reducing cardiovascular mortality and recurrent CV events versus placebo. This is a material clinical trial failure for a drug in late-stage development affecting a significant patient population (300,000–500,000 worldwide). While not a discrete event type like M\u0026A or restatement, the failure of a major Phase III program is a material operational/clinical development outcome that would affect investor assessment of the company's pipeline and near-term revenue prospects.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-09","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":14978,"accession_number":"0001654954-26-006554","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AstraZeneca announced that its Phase III CARDIO-TTRansform trial for Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy \"did not meet the primary efficacy endpoint\" of reducing cardiovascular mortality and recurrent CV events versus placebo. This is a material clinical trial failure for a drug in late-stage development affecting a significant patient population (300,000–500,000 worldwide). While not a discrete event type like M\u0026A or restatement, the failure of a major Phase III program is a material operational/clinical development outcome that would affect investor assessment of the company's pipeline and near-term revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:27:48.098964+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-07-09"}]}